ACG to invest $200 million in US hard-shell capsule manufacturing

The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta

FDA approves Roche’s kidney inflammation drug

Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study

Pfizer’s Braftovi+Mektovi shows sustained long-term survival in patients with advanced lung cancer

Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population

Bajaj Healthcare posts Q2 FY26 PAT at Rs. 11.10 Cr

Bajaj Healthcare has reported total income of Rs. 149.56 crore during the period ended September 30, 2025

TTK Healthcare reports Q2 FY26 net profit at Rs. 20.38 Cr

TTK Healthcare has reported total income of Rs. 222.58 crore during the period ended September 30, 2025

RPG Life Sciences posts Q2 FY26 PAT at Rs. 36.85 Cr

RPG Life Sciences has reported total income of Rs. 186.22 crore during the period ended September 30, 2025

Johnson & Johnson’s Rybrevant shows 45% response rate in HNSCC

Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab

FDA approves Alembic’s Triamcinolone Acetonide injectable suspension USP, 40 mg/mL

Triamcinolone Acetonide injectable suspension USP is indicated for various autoimmune, inflammatory, and other conditions

Cupid achieves CE (EU IVDR) certification for pregnancy and syphilis test kits

Pfizer’s TUKYSA boosts front-line outcomes, extending progression-free survival in HER2+ metastatic breast cancer

Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents